(Reuters) - AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of ...
Zacks.com on MSN1d
AstraZeneca Stock Up Almost 14% in 6 Months: Time to Buy?AstraZeneca AZN stock has risen 13.6% in the past six months, outperforming an increase of 7.1% for the industry. AstraZeneca ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
In several short films directed by Reed Morano, the “What science can do” campaign features stories from a cancer patient and an asthma patient.
AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...
AstraZeneca PLC AZN shares rallied 1.33% to £117.20 Thursday, on what proved to be an all-around great trading session for ...
AstraZeneca is extending its work with Immunai through a multiyear collaboration that aims to implement its ...
The FDA has approved AstraZeneca's Tagrisso for treating unresectable, Stage III EGFR-mutated non-small cell lung cancer, ...
In June, at the American Society of Clinical Oncology (ASCO) conference in Chicago, when AstraZeneca discussed results from a ...
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...
The Zacks Daily presents the best research output of our analyst team. Today's Daily features new research reports on 16 ...
AstraZeneca’s FluMist approval for self-administration could increase flu vaccine uptake: GlobalData
According to GlobalData, the US vaccination rate for seasonal influenza during the 2023-2024 season was estimated to be 47%, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback